Pivot Park Screening Centre unveils new insulin-regulated aminopeptidase inhibitors
Pivot Park Screening Centre unveils the discovery of new inhibitors of insulin-regulated aminopeptidase by a high-throughput screening of 400,000 drug-like compounds.
Pharming is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact
Awards on 8 June 2024.
Press release: Ardena’s Nanomedicines Facility Marks €20 Million Expansion with first GMP approval
Ardena has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
Flindr Therapeutics B.V. announces a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer.
Unveiling Pivot Park’s new Business Hub
Discover Pivot Park’s new Business Hub, uniting 14 companies in the campus center. Empowering biopharmaceutical startups and scale-ups for collaborative innovation in pioneering R&D. Join us at the forefront of advancing medicine.
Introducing the Pedro Hermkens Stipend: Empowering professional growth at Pivot Park
At Pivot Park, we recognize the importance of investing in the ongoing development of our community members. The Pedro Hermkens Stipend offers our community a maximum award of 1,000 euros, providing vital support for their career endeavours.
Ardena was contracted by Race to manufacture the cGMP RC220 drug product to ensure that it meets the exacting standards required by major global regulatory authorities for human clinical use, including the European Medicines Agency (EMA), the US Food & Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA).
Pivot Park Screening Centre presents cutting-edge research on the quest for antiplatelet drugs. The focus of the research lies in ultra-high throughput-based screening for the discovery of antiplatelet drugs affecting receptor dependent calcium signaling dynamics.
Glycostem Therapeutics unveils research on how Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditions.
Oncolines proudly announces its contribution alongside the Institute of Research in Biomedicine (IRB) and OM Pharma in shedding light on the intricate workings of OM-85, commonly known as Broncho-Vaxom®.
Oncolines contributes to publication in Nature Communications
Oncolines contributes to publication in Nature Communications. Identification of first-in-class, potent and selective CK1α degrader.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
